Introduction {#S0001}
============

Pediatric germ cell tumors (GCT) represent about 3% of all childhood malignancies for children less than 15 years of age; this incidence increases to about 15% in adolescence and young adulthood.[@CIT0001] These tumors may arise from the gonads or extra-gonadal tissue. There are five subtypes of pediatric GCT: teratoma, germinoma, yolk sac tumor (also known as endodermal sinus tumor), embryonal carcinoma, and choriocarcinoma, as well as mixed malignant subtypes.[@CIT0001]--[@CIT0003] Although infantile and pediatric GCT are biologically distinct from GCT of older adolescents and adults, treatment for all GCT is essentially the same and generally grounded in large doses of platinum-based chemotherapy combined with surgery. Thus, younger patients suffer more severe side effects from treatment.[@CIT0002],[@CIT0004]

Predisposition to developing ovarian and testicular teratomas has been reported in families with multiple affected members.[@CIT0003] While the exact mechanisms underlying GCT development remain unclear, abnormalities in the *KIT-ligand (KITLG)* and *KRAS* pathway are thought to play a role.[@CIT0005],[@CIT0006] Amplifications in chromosome 12p and X chromosome have been implicated in nonseminomatous GCT. Yolk sac tumors also show gains in chromosomes 1q, 11q, 20q, as well as gains in chromosome 22; losses in chromosome 1p, 6q, and 16q have also been reported.[@CIT0007]

There is evidence to support that methylation plays a role in GCT biology, and that methylation patterns identified in GCT can distinguish the five sub-types.[@CIT0008] Based on prevailing literature and our experience with families enriched with germ cell malignancies, germline variant that predisposes a progenitor germ cell to malignant transformation or makes the microenvironment more permissive to tumor growth is likely to be a strong candidate for unraveling the complex biology of these cancers.

Next-generation sequencing (NGS) has significantly advanced our understanding of the genomic landscape of familial cancers.[@CIT0002] Combining deep phenotyping with deep sequencing has the potential to identify key oncogenes involved with rare and aggressive cancers. The goal of this study was to apply these techniques to 3 independent families from Finland with an extensive history of neoplasia, but no known genomic lesions. Of interest, the people of Finland have a unique ancestry marked by a population bottleneck followed by geographic isolation on a peninsula.[@CIT0009] Consequently, the Finnish population has an enrichment in rare genetic variants. Our study leverages the distinctive genetics of this population.

Patients and Methods {#S0002}
====================

Subject Enrollment {#S0002-S2001}
------------------

Three families from Finland were enrolled for this study. The study was approved by the ethical committee of Helsinki University Hospital, Helsinki, Finland. Written informed consent was obtained from all subjects and/or their parents, as well as the relatives from whom the samples were obtained for this study. A total of 22 unique subjects were sequenced across the 3 families, n=4, n=11, and n=7, respectively ([[Supplemental Table 1](http://www.dovepress.com/get_supplementary_file.php?f=245093.xlsx)]{.ul}). Family 1 proband had a malignant ovarian teratoma, diagnosed at 8 years of age, with a family history of ovarian teratoma ([[Supplemental Table 1](http://www.dovepress.com/get_supplementary_file.php?f=245093.xlsx)]{.ul}). Family 2 proband was diagnosed with a neonatal sacrococcygeal teratoma and a subsequent yolk sac tumor at 1.5 years of age, with a family history of malignancies (NOS) ([[Supplemental Table 1](http://www.dovepress.com/get_supplementary_file.php?f=245093.xlsx)]{.ul}). Family 3 had a proband with a malignant testicular teratoma, diagnosed at 1 year of age, with a family history of malignancies (NOS) ([[Supplemental Table 1](http://www.dovepress.com/get_supplementary_file.php?f=245093.xlsx)]{.ul}). Peripheral blood was collected from each proband and family members.

De-identified analysis of genomic data from the consented patients was conducted at Nemours (Dr. Crowgey) with IRB research determination (IRB\# 1327922--1).

Whole-Genome Sequencing (WGS) and Genome Alignment {#S0002-S2002}
--------------------------------------------------

Whole-genome sequencing was conducted at Washington University School of Medicine by the McDonnell Genome Institute. Whole-genome sequencing was conducted using the NovaSeq 6000 high-throughput sequencing platform (Illumina, San Francisco, CA) at a depth of coverage of 30X. Samples were prepared using the TruSeq whole genome library preparation (Illumina). Fastq files were processed via fastqc for data quality (Babraham Institute) and trimmed based on adaptor sequences and quality (cutadapt). Trimmed reads were mapped to the human genome hg19 via bwa mem.[@CIT0010] Genome analysis toolkit (GATK) best practices, base quality score recalibration, indel realignment, and duplicate read removal were followed to generate a combined variant call file (VCF) using Haplotyper for all samples analyzed.[@CIT0011]--[@CIT0013]

Variant Annotation and Data Analysis {#S0002-S2003}
------------------------------------

VCFs were annotated using VarSeq version 2.2.0 (Golden Helix^®^). Specifically, variants were annotated using: ExAC Variant Frequencies 0.3, gnomAD exomes and genome variant frequencies 2.1.1,[@CIT0014] dbSNP 151 ([<http://www.ncbi.nlm.nih.gov/SNP/>]{.ul}), Ensemble Genes 87, and functional predictions were determined via sift,[@CIT0015] polyphen2 HVAR,[@CIT0016] mutation taster,[@CIT0017] mutationAssessor,[@CIT0018] FATHMM,[@CIT0019] and FATHMM MKL coding. At least three of the functional predictions needed to predict the variant as damaging. Variants were filtered based on the following inheritance patterns when appropriate autosomal recessive, and de novo, using the following criteria: read depth \>10, genotype qualities \>20, MAF ExAC \<0.01, MAF gnomAD \<0.01, and effect of mutation (loss of function or missense for coding variants). The same logic was applied for non-coding variants located in introns and non-exonic (intergenic) locations.

A variant was considered as autosomal recessive for proband 1 and 2 if both the mother and father were carriers (0/1), unaffected siblings were either carriers or wildtype (0/1 or 0/0), and the proband was homozygous alternative (1/1). Additionally, for family 2 proband, the unaffected extended family members in the pedigree were used to further filter out variants if they were a homozygous alternative (1/1) genotype. Variants were considered as de novo for proband 1 and 2 if both the mother and father were homozygous wildtype (0/0), and the unaffected siblings were also homozygous wildtype (0/0). Additionally, for family 2 proband, the unaffected extended family members in the pedigree were used to further filter out variants if they were a carrier (0/1). For proband 3, unfortunately the mother's sample was not available for sequencing. The same logic as above for probands 1 and 2 was applied, except that the mother's parents' genotypes were used in replacement.

Results {#S0003}
=======

Family 1 {#S0003-S2001}
--------

Four subjects were sequenced in Family 1 pedigree: mother, father, proband (ovarian teratoma), and unaffected sibling ([Figure 1](#F0001){ref-type="fig"}). A history of ovarian teratoma was noted by the primary care physician ([[Supplemental Table 1](http://www.dovepress.com/get_supplementary_file.php?f=245093.xlsx)]{.ul}); however, germline samples from these extended family members were not available for sequencing. Using an autosomal recessive analysis, three variants of interest were identified in the following genes: *CD109* (rs7741152), *IKBKB* (rs140485496), and *CTNNA3* (rs192093851) ([Table 1](#T0001){ref-type="table"}). All of the variants identified were rare within the other Finnish families analyzed with *CD109* and *IKBKB* alleles only identified in Family 1, and 1 allele count outside of Family 1 for rs192093851 (*CTNNA3*). It was noted that all three variants had a \<0.01 minor allele frequency (MAF) within the gnomAD database; however, they were \>0.01 within the Finnish-specific genomes within gnomAD ([Table 1](#T0001){ref-type="table"}). Inhibitor of NF-κB kinase subunit beta (*IKBKB)* is associated with immunodeficiency disorders (IMD15B and 15A) and is a serine kinase that plays a key role in the NF-κB signaling pathway. Gene variants and expression data have linked *IKBKB* with prostate and ovarian cancers.[@CIT0020] Of interest, *IKBKB* has been associated with *KRAS*, which is a known oncogene linked to GCTs.[@CIT0021]Table 1Rare Autosomal Recessive and De Novo Variants Identified in Family 1 ProbandInhertiance PattermChr:PositionRef/AltIDProbandFatherMotherSisterGene NamesHGVS c. (Clinically Relevant)HGVS p. (Clinically Relevant)EffectGnomADGnomAD European Finnish91/9894/9892/9893/98Autosomal recessive6:74475675G/Ars77411521/10/10/10/1CD109NM_133493.4:c.1130G\>ANP_598000.2:p.Gly377Aspmissense_variant0.00790.019328:42178280C/Trs1404854961/10/10/10/1IKBKBNM_001556.2:c.1606C\>TNP_001547.1:p.Arg536Trpmissense_variant0.003730.0227910:68979466C/Ars1920938511/10/10/10/0CTNNA3NM_013266.3:c.742G\>TNP_037398.2:p.Ala248Sermissense_variant0.003440.02396De novo1:6505837AG/-0/10/00/00/0ESPNNM_031475.2:c.1306_1307delAGNP_113663.2:p.Ser436Leufsframeshift_variant1:109268468-/CCGTArs13420228520/10/00/00/0FNDC7NM_001144937.1:c.952_953insCCGTANP_001138409.1:p.Val318Alafsframeshift_variant0.001101:109268470T/Ars12236923200/10/00/00/0FNDC7NM_001144937.1:c.955T\>ANP_001138409.1:p.Phe319Ilemissense_variant0.0004301:109268473GTG/-rs12487599110/10/00/00/0FNDC7NM_001144937.1:c.958_960delGTGNP_001138409.1:p.Val320delinframe_deletion0.0004101:109268476-/AAAAAArs12251238620/10/00/00/0FNDC7NM_001144937.1:c.960_961insAAAAAANP_001138409.1:p.Lys321_Ser322insLysLysinframe_insertion0.0004304:190878556-/A0/10/00/00/0FRG1NM_004477.2:c.435_436insANP_004468.1:p.Met147Asnfsframeshift_variant11:1213565-/A0/10/00/00/0MUC5ACNM_001304359.1:c.2680_2681insANP_001291288.1:p.Pro894Hisfsframeshift_variant11:1213571-/AACCCGGGrs13003560080/10/00/00/0MUC5ACNM_001304359.1:c.2686_2687insAACCCGGGNP_001291288.1:p.Thr896Lysfsframeshift_variant0.001580.00383712:109017014T/Grs13733414860/10/00/00/0SELPLGNM_001206609.1:c.1118A\>CNP_001193538.1:p.Tyr373Sermissense_variant0.00128017:27013754G/A0/10/00/00/0SUPT6HNM_003170.4:c.2647G\>ANP_003161.2:p.Glu883Lysmissense_variant18:34298343ACCTTTCTGGGTTTG/-0/10/00/00/0FHOD3NM_001281740.2:c.3082_3096delACCTTTCTGGGTTTGNP_001268669.1:p.Thr1028_Leu1032delinframe_deletion12:40897291G/Ars12762364790/10/00/00/0MUC19NM_173600.2:c.18907G\>ANP_775871.2:p.?missense_variant0.005810.00307614:22102317G/Trs2007926440/10/00/00/0OR10G2NM_001005466.2:c.682C\>ANP_001005466.2:p.His228Asnmissense_variant0.006460.00091941:151317205G/Crs7475552140/10/00/00/0RFX5NM_000449.3:c.352C\>GNP_000440.1:p.Arg118Glymissense_variant00 Figure 1Family 1 pedigree. Four family members were sequenced via whole-genome sequencing: proband, mom, dada, and unaffected sister. The proband, black circle, was a malignant ovarian teratoma. Females are represented as circles; males are represented as squares. The number next to the pedigree represents the de-identified subject ID.

The de novo analysis identified 14 rare variants within proband one across 10 unique genes ([Table 1](#T0001){ref-type="table"}). Nine of the variants had known RefSeq (rs\#) identification numbers in the dbSNP database and MAF of \>0.01 in the gnomAD genome database as well as within the Finnish-specific genomes within gnomAD ([Table 1](#T0001){ref-type="table"}). Of interest, *SUPT6H*, a histone chaperone, has previously been shown to control estrogen-related transcription and linked to cancer.[@CIT0022] Additionally, *MUC5AC* has been associated with ovarian tumors[@CIT0023] and *FRG1* expression levels have been shown to be aberrant in several cancers.

Family 2 {#S0003-S2002}
--------

Eleven subjects were sequenced in Family 2 pedigree: proband (sacrococcygeal teratoma -- yolk sac tumor), unaffected brother with a benign sacrococcygeal cyst, unaffected sister, mother, father, two paternal aunts, paternal grandmother, 2 paternal great aunts, and a paternal cousin ([[Supplemental Table 1](http://www.dovepress.com/get_supplementary_file.php?f=245093.xlsx)]{.ul}; [Figure 2](#F0002){ref-type="fig"}). Of interest, the unaffected brother and nephew (unaffected sister) have a history of benign dermoid cysts (sacrococcygeal and ophthalmic area). Furthermore, the proband's great grandfather (maternal side) had prostate cancer, and a great grandmother with stomach cancer, who has a daughter with leukemia and a granddaughter with cancer. An autosomal recessive analysis identified two rare variants in the following genes *LONRF2* (rs116702638) and *ANO7* (rs148609049) ([Table 2](#T0002){ref-type="table"}). It was noted that all three variants had a \<0.01 MAF within the gnomAD database; however, they were \>0.01 within the Finnish-specific genomes within gnomAD ([Table 1](#T0001){ref-type="table"}). Variant rs148609049 has previously been published as a germline variant that associates with significantly shorter survival rates in prostate cancer subjects.[@CIT0024] Aberrant methylation patterns for LON peptidase N-terminal domain and RING finger protein 2 (*LONRF2*) have been noted in rectal adenocarcinoma. Of interest, *ANO7* is associated with aggressive prostate cancer.[@CIT0024]Table 2Rare Autosomal Recessive and De Novo Variants Identified in Family 2 ProbandInhertiance PatternChr:PositionRef/AltIDFatherMotherProbandSisterBrotherAuntAuntGrandmaGreat auntGreat auntCousinGene NamesHGVS c. (Clinically Relevant)HGVS p. (Clinically Relevant)EffectGnomADGnomAD European (Finnish)95/9896/9897/98105/98106/98108/98112/98107/98111/98110/98109/98Autosomal recessive2:100915330G/Trs1167026380/10/11/1ʹ0/10/10/10/10/10/10/10/0LONRF2NM_198461.3:c.1444C\>ANP_940863.3:p.His482Asn0.0083770.02012:242128114C/Trs1486090490/10/11/1ʹ0/00/10/00/10/10/00/10/0ANO7NM_001001891.3:c.88C\>TNP_001001891.2:p.Arg30Ter0.0076570.03571De novo1:152278769-/CCrs12052808540/00/00/10/00/00/00/00/00/00/00/0FLGNM_002016.1:c.8593_8594insGGNP_002007.1:p.Ala2865Glyfsframeshift_variant0.0034390.023966:43155555CC/-rs12353429300/00/00/10/00/00/00/10/00/00/00/0CUL9NM_015089.3:c.1686_1687delCCNP_055904.1:p.Leu563Alafsframeshift_variant0.00389806:43155558-/ACGrs12171183050/00/00/10/00/00/00/10/00/00/00/0CUL9NM_015089.3:c.1688_1689insACGNP_055904.1:p.Leu563_Leu564insArgdisruptive_inframe_insertion0.00612601:152278771TG/-rs14077033980/00/00/10/00/00/00/00/00/00/00/0FLGNM_002016.1:c.8590_8591delCANP_002007.1:p.His2864Cysfsframeshift_variant1:152278831-/TTGrs14487283600/00/00/10/00/00/00/00/00/00/00/0FLGNM_002016.1:c.8531_8532insCAANP_002007.1:p.Glu2844delinsAspLysdisruptive_inframe_insertion2:129025758C/Ars1429194290/00/00/10/00/00/00/00/00/00/00/0HS6ST1NM_004807.2:c.1214G\>TNP_004798.3:p.Ser405Ilemissense_variant0.0016220.00089783:195506483TGTCGGTGACAGGAAGGGGGGTGGCGTGACCTGTGGATGCTGAGGAAC/-rs15603011800/00/00/10/00/00/00/00/00/00/00/0MUC4NM_018406.6:c.11921_11968delGTTCCTCAGCATCCACAGGTCACGCCACCCCCCTTCCTGTCACCGACANP_060876.5:p.Arg3974_Thr3990delinsProdisruptive_inframe_deletion3:195512233-/GCCGAGGAAACGTTGGTGACAGGAAGACGGGTGGTGTCACCTGTGGAArs5296366800/00/00/10/00/00/00/00/00/00/00/0MUC4NM_018406.6:c.6218_6219insTTCCACAGGTGACACCACCCGTCTTCCTGTCACCAACGTTTCCTCGGCNP_060876.5:p.Gly2076_His2077insAspThrThrArgLeuProValThrAsnValSerSerAlaSerThrGlydisruptive_inframe_insertion0.0000404306:43155547C/Trs13000186490/00/00/10/00/00/00/00/00/00/00/0CUL9NM_015089.3:c.1678C\>TNP_055904.1:p.Leu560Phemissense_variant0.00470406:43155560-/GArs12641392310/00/00/10/00/00/00/00/00/00/00/0CUL9NM_015089.3:c.1690_1691insGANP_055904.1:p.Leu564Argfsframeshift_variant6:43155560T/Crs14894051890/00/00/10/00/00/00/00/00/00/00/0CUL9NM_015089.3:c.1691T\>CNP_055904.1:p.Leu564Promissense_variant006:43155563ACT/-rs11895055690/00/00/10/00/00/00/00/00/00/00/0CUL9NM_015089.3:c.1694_1696delACTNP_055904.1:p.Asn565_Ser566delinsThrdisruptive_inframe_deletion0.0047410.0000398511:1093483GT/-rs7472444210/00/00/10/00/00/00/00/00/00/00/0MUC2NM_002457.4:c.5296_5297delGTNP_002448.4:p.Val1766Thrfsframeshift_variant12:11546859-/CCTTGAGGCTGGTTGCCTCCTTGTGGGGGTGCTCCTTGTGGCTTTCCTGGAGGAGG0/00/00/10/00/00/00/00/00/00/00/0PRB2NM_006248.3:c.153_154insCCTCCTCCAGGAAAGCCACAAGGAGCACCCCCACAAGGAGGCAACCAGCCTCAAGGNP_006239.3:p.Ser52Profsframeshift_variant12:40876971C/Ars7691091660/00/00/10/00/00/00/00/00/00/00/0MUC19NM_173600.2:c.10217C\>ANP_775871.2:p.?missense_variant0.0028070.000319312:40876979A/Crs12730781870/00/00/10/00/00/00/00/00/00/00/0MUC19NM_173600.2:c.10225A\>CNP_775871.2:p.?missense_variant0.001104019:10908156TCAGAGCTG/-rs12951516300/00/00/10/00/00/00/00/00/00/00/0DNM2NM_001005360.2:c.1336-1006_1336-998delTCAGAGCTGinframe_deletion0.0091960.00020419:41811728-/CCCCCCCA0/00/00/10/00/00/00/00/00/00/00/0HNRNPUL1NM_007040.5:c.2409_2410insCCCCCCCANP_008971.2:p.Thr804Profsframeshift_variant19:52888076-/ATGAGGTCAGGAGATCGAGACCATCCTGGCTAACAAGGTG0/00/00/10/00/00/00/00/00/00/00/0ZNF880NM_001145434.1:c.1242_1243insATGAGGTCAGGAGATCGAGACCATCCTGGCTAACAAGGTGNP_001138906.1:p.Lys415Metfsframeshift_variant Figure 2Family 2 pedigree. Eleven subjects were sequenced via whole-genome sequencing: proband, unaffected brother, unaffected sister, mother, father, two paternal aunts, paternal grandmother, 2 paternal great aunts, and a paternal cousin. The proband, black circle, was a sacrococcygeal teratoma -- yolk sac tumor. Females are represented as circles; males are represented as squares. The number next to the pedigree represents the de-identified subject ID.

The de novo analysis identified 19 rare variants within proband two across 10 unique genes ([Table 2](#T0002){ref-type="table"}). Sixteen of the variants were found in dbSNP with MAF of \>0.01 in the gnomAD genome database and within the Finnish-specific genomes within gnomAD ([Table 2](#T0002){ref-type="table"}). Of interest *HS6ST1, PRB2*, and *DNM2* have been previously linked to cancers.[@CIT0025],[@CIT0026]

Family 3 {#S0003-S2003}
--------

Seven subjects were sequenced in Family 3 pedigree: proband (malignant testicular teratoma), un-affected siblings, dad, uncle (maternal), grandparents (maternal) ([[Supplemental Table 1](http://www.dovepress.com/get_supplementary_file.php?f=245093.xlsx)]{.ul}; [Figure 3](#F0003){ref-type="fig"}). Two InDels were identified in this family using an autosomal recessive pattern in the following genes ([Table 3](#T0003){ref-type="table"}): *CRIPAK* and *KRTAP5-7. CRIPAK* encodes for a cysteine-rich PAK1 inhibitor protein that negatively regulates *PAK1* expression. PAKs are a family of proteins that are involved in cytoskeletal dynamics, cell survival and proliferation and have been well associated with cancers.[@CIT0027] The de novo analysis identified 22 rare variants in 17 unique genes. Aberrant expression levels of *CACNA1B* have previously been associated with cancers.[@CIT0028] Of interest, *TXNDC2* is solely expressed in testis and is predicted to regulate disulfide bonds, and *TFE3* is a transcription factor linked to cancers and is ubiquitous in fetal and adult tissues.Table 3Autosomal Recessive and De Novo Variants Identified in Family 3 ProbandInhertiance PatternChr:PosRef/AltIDProbandSisterFatherUncleGrandmotherSisterGrandfatherGene NamesHGVS c. (Clinically Relevant)HGVS p. (Clinically Relevant)EffectGnomADGnomAD European Finnish100/98101/98102/98103/98104/9898/9899/98Autosomal recessive4:1388626ACGTGCCGATGCGGArs2017322111/1'0/00/00/00/00/00/0CRIPAKMissense0.0011050.00289311:71238676CTGCTGCCAGTCCAGCTGCTGTAAGCCCTGCTGCTGCCAGTCCAGCTGCTGTAAGCCCTGrs13932206201/1'0/10/10/00/10/00/0KRTAP5-7NM_001012503.1:c.329_330insCTGCTGCCAGTCCAGCTGCTGTAAGCCCTGCTGCTGCCAGTCCAGCTGCTGTAAGCCCTGNP_001012521.1:p.Cys132_Ser133insGlnSerSerCysCysLysProCysCysCysGlnSerSerCysCysLysProCysCysCysMissense0.00065830De novo1:152284478A/Grs1998885880/10/00/00/00/00/00/0FLGNM_002016.1:c.2884T\>CNP_002007.1:p.Trp962Argmissense_variant0.026480.0006091:240371009T/Crs2009755940/10/00/00/00/00/00/0FMN2NM_001305424.1:c.2909T\>CNP_001292353.1:p.Leu970Promissense_variant0.0027570.00004993:195507970G/Ars2010005180/10/00/00/00/00/00/0MUC4NM_018406.6:c.10481C\>TNP_060876.5:p.Pro3494Leumissense_variant0.00047970.0001983:195507971G/Ars7677764700/10/00/00/00/00/00/0MUC4NM_018406.6:c.10480C\>TNP_060876.5:p.Pro3494Sermissense_variant0.000407403:195507973A/Crs2003684310/10/00/00/00/00/00/0MUC4NM_018406.6:c.10478T\>GNP_060876.5:p.Ile3493Sermissense_variant0.0019080.00010924:9245723A/Trs14119512810/10/00/00/00/00/00/0USP17L17NM_001256857.1:c.119A\>TNP_001243786.1:p.Lys40Metmissense_variant0.0012870.00086815:140222138-/CCAACTGATCTGATATATTGTATAGTTTAATAGCTTCTCTAGTCATCTTAAACAGGGTTGGrs7822054370/10/00/00/00/00/00/0PCDHA1NM_018900.3:c.2394+53868_2394+53869insCCAACTGATCTGATATATTGTATAGTTTAATAGCTTCTCTAGTCATCTTAAACAGGGTTGGNP_061734.1:p.Ser411Thrfsframeshift_variant0.000420.00029057:97619354A/Crs13901126270/10/00/00/00/00/00/0OCM2NM_006188.3:c.61+2T\>Gsplice_donor_variant0.0000755108:12286291C/Trs12110976480/10/00/00/00/00/00/0FAM86B2NM_001137610.1:c.593G\>ANP_001131082.1:p.Arg198Glnmissense_variant0.0024660.00075549:140773613-/ACGACACGGAGCCCTATTTCATCGGGATCTTTrs3702371720/10/00/00/00/00/00/0CACNA1BNM_000718.3:c.390+1_390+2insACGACACGGAGCCCTATTTCATCGGGATCTTTsplice_donor_variant0.0051130.00384211:1212902C/Grs2002925170/10/00/00/00/00/00/0MUC5ACNM_001304359.1:c.2018C\>GNP_001291288.1:p.Thr673Sermissense_variant0.0025780.0032811:1213367G/Ars7484244150/10/00/00/00/00/00/0MUC5ACNM_001304359.1:c.2483G\>ANP_001291288.1:p.Arg828Hismissense_variant0.00060290.0000764811:1266007T/Crs7747682770/10/00/00/00/00/00/0MUC5BNM_002458.2:c.7897T\>CNP_002449.2:p.Trp2633Argmissense_variant0.000098610.0000406811:1266815G/Ars2008749000/10/00/00/00/00/00/0MUC5BNM_002458.2:c.8705G\>ANP_002449.2:p.Arg2902Hismissense_variant0.00066340.000252211:1269763C/Ars2005311330/10/00/00/00/00/00/0MUC5BNM_002458.2:c.11653C\>ANP_002449.2:p.Arg3885Sermissense_variant0.0026260.00807411:1605904-/CCCCCCACAAGAACCGCAGCCCCCCrs13168182040/10/00/00/00/00/00/0KRTAP5-1NM_001005922.1:c.576_577insGGGGGGCTGCGGTTCTTGTGGGGGGNP_001005922.1:p.Ser193Glyfsframeshift_variant0.00003881011:64032525C/G0/10/00/00/00/00/00/0PLCB3NM_000932.2:c.2755C\>GNP_000923.1:p.Arg919Glymissense_variant12:40882472-/AGAGACAATTGGACTATCAGCTGGAGTGATrs11598250880/10/00/00/00/00/00/0MUC19NM_173600.2:c.15716_15717insAGAGACAATTGGACTATCAGCTGGAGTGATNP_775871.2:p.?disruptive_inframe_insertion0014:19378000A/Grs7610483700/10/00/00/00/00/00/0OR11H12NM_001013354.1:c.407A\>GNP_001013372.1:p.Asp136Glymissense_variant0.003980.000280818:9887384T/Crs14428657360/10/00/00/00/00/00/0TXNDC2NM_001098529.1:c.908T\>CNP_001091999.1:p.Leu303Promissense_variant0.0011970.000179318:76754481-/CCCCCCCCCCCCCCCCG0/10/00/00/00/00/00/0SALL3NM_171999.3:c.2489_2490insCCCCCCCCCCCCCCCCGNP_741996.2:p.Ser832Profsframeshift_variantX:48887808T/Crs12865617190/10/00/00/00/00/00/0TFE3NM_006521.5:c.1589A\>GNP_006512.2:p.Glu530Glymissense_variant Figure 3Family 3 pedigree. Seven subjects were sequenced via whole-genome sequencing: proband, unaffected siblings, data, maternal uncle, and maternal grandparents. Females are represented as circles; males are represented as squares. The number next to the pedigree represents the de-identified subject ID.

Non-Coding Variant Analysis {#S0003-S2004}
---------------------------

Rare variants (gnomAD MAF \<0.01) in non-coding regions of the genome were analyzed, introns or intergenic regions. Heterozygous variants were only considered for a proband if the parents and unaffected siblings were homozygous wildtype (0/0), and homozygous variants were only considered for a proband if the parents and unaffected siblings were homozygous wildtype or heterozygous (0/1). A variant was considered as known if it was listed in dbSNP 151. The range of intronic variants detected per proband was 2526--3439 (left side, [Figure 4](#F0004){ref-type="fig"}), with the majority of variants per proband were known heterozygous. The range of intergenic variants detected was 8320--10826 (right side, [Figure 4](#F0004){ref-type="fig"}), with the majority of the variants also being known heterozygous.Figure 4Non-coding variants identified in the probands. Rare non-coding variants were identified in introns (left bars) and non-exonic regions (intergenic, right bars) per each proband. A variant was considered to be known if it was listed in dbSNP 151. Known homozygous variants are in blue, novel homozygous variants are in orange, known heterozygous variants are in grey, and novel heterozygous variants are in yellow.

Discussion {#S0004}
==========

GCT are primarily sporadic cancers in early childhood or adolescence with a variety of subtypes. Thus, the mechanisms involved in GCT are poorly understood. The identification of families with relatively little admixture and multiple GCT cases offers an opportunity to identify novel genes that may drive or modulate tumor onset and subtype. In this study, we performed WGS on three such non-consanguinous families from Finland, where the proband in each family had a different GCT subtype. The NGS analysis revealed different genes with an autosomal recessive or de novo inheritance pattern in each family.

Family 1, proband with malignant ovarian teratoma, analysis yielded three potential autosomal recessive variants of interest in the following genes: *CD109, IKBKB*, and *CTNNA3*. Although variants had a MAF \<0.01 in the gnomAD genome database, they did have higher MAF in the Finnish-specific genome data. We hypothesize that germline variants might cause a predisposition, but these higher allele frequencies in the Finnish population indicate that a second hit/additional variant in combination would be necessary. CD109 is highly associated with cancers[@CIT0029] and aberrant expression patterns are associated with squamous cell carcinoma.[@CIT0030] *IKBKB* is a potent activator of the NF-kB pathway, which plays a major regulatory role during developmental transitions and the ability of KRAS to transform tissues with aberrant NF-κB signaling is well established.[@CIT0031] Additionally, dysregulation of microRNAs that target IKBKB has been associated with ovarian tumors.[@CIT0032] The de novo variant analysis identified rare variants within the gnomAD Finnish data, with the most interesting gene candidates being *SUPT6H*, a histone chaperone, *MUC5AC* has been associated with ovarian tumors,[@CIT0023] and *FRG1*.

An autosomal recessive analysis for family 2 yielded two potential variants of interest in the following genes: *LONRF2*, and *ANO7. ANO7* encodes for the protein anoctamin-7, which has calcium-dependent phospholipid scramblase activity. The variant detected is a loss of function variant resulting in a stop gain at amino acid 30 in the translated protein and has previously been published as a germline variant that associates with significantly shorter survival rates in prostate cancer subjects.[@CIT0024] The de novo analysis identified rare variants within the gnomAD Finnish data and included *HS6ST1, PRB2*, and *DNM2*, which all have been previously linked to cancers.[@CIT0025],[@CIT0026]

Family 3 had variants of interest identified in *CRIPAK and KRTAP5-7*. CRIPAK is a novel interacting partner of PAK1.[@CIT0033] *PAK1*, also referred to as p21-activated kinase 1, is a complex gene involved in many cellular signaling pathways including mitosis. Recent studies have described *PAK1* has a relevant oncogene in ovarian carcinoma[@CIT0034] and breast carcinoma,[@CIT0035] phenotypes recorded within this family history. However, the pedigree and variant results for Family 3's proband suggest a potential sporadic case of a neoplasm. A de novo analysis did identify rare variants in *TXNDC2*, which is solely expressed in testis and is predicted to regulate disulfide bonds, and *TFE3*, a transcription factor linked to pediatric cancers that is ubiquitously expressed in fetal and adult tissues.

A current limitation of this study is the lack of functional studies, which are required to further validate the biological significance of the variants identified. It is challenging to functionally validate these types of complex variants associated with a complex phenotype, as models are difficult to establish. Unfortunately, tumor testing, which looks for abnormalities in cancer cells, was not conducted at the time of diagnosis for the probands. These data could have provided additional insight for interpreting the germline variants identified. Furthermore, the non-coding variant analysis identified numerous variants that are difficult to interpret without additional functional testing.
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